Experimental Drug LMV-601 Inhibits HPV Replication and Abnormal Cell Growth in Laboratory Study

By Liz Highleyman | http://hivandhepatitis.com | http://hivandhepatitis.com/2010_conference/icaac/docs/1005_b.html

SUMMARY: Lumavita’s LMV-601, an investigational PC-PLC inhibitor, reduced expression of high-risk human papillomavirus (HPV) types 16, 18, and 31, and over time improved pre-cancerous cervical cell abnormalities in a laboratory study, researchers reported at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010) last month in Boston.